Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (551-560 of 962) with videos related to

Pageof 97
Sort By:
Journal of the American College of Cardiology|March 23, 2019
Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-ITDeepak L Bhatt, Ph Gabriel Steg, Michael Miller, et al.
Critical Pathways in Cardiology|August 31, 2010
Prior cardiovascular interventions are not associated with worsened clinical outcomes in patients with symptomatic atherothrombosisWilliam E Boden, Gregory S Cherr, Kim A Eagle, et al.
Journal of the American College of Cardiology|January 14, 2017
Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary InterventionMuthiah Vaduganathan, Robert A Harrington, Gregg W Stone, et al.
Journal of the American College of Cardiology|October 2, 2012
Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgeryChristoph Varenhorst, Ulrica Alström, Benjamin M Scirica, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|October 9, 2017
Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trialsMuthiah Vaduganathan, Robert A Harrington, Gregg W Stone, et al.
Circulation. Cardiovascular Interventions|April 11, 2018
Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)Elliott M Groves, Deepak L Bhatt, Philippe Gabriel Steg, et al.
Heart (British Cardiac Society)|February 6, 2016
Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary interventionMatthijs A Velders, Jérémie Abtan, Dominick J Angiolillo, et al.
Journal of Thrombosis and Thrombolysis|June 14, 2017
Platelet-related biomarkers and their response to inhibition with aspirin and p2y<sub>12</sub>-receptor antagonists in patients with acute coronary syndromeAngela Lowenstern, Robert F Storey, Megan Neely, et al.
Clinical Chemistry|December 10, 2016
Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary SyndromeDaniel Lindholm, Stefan K James, Maria Bertilsson, et al.
Journal of the American Heart Association|September 17, 2021
Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre-Specified Analysis of the GLOBAL LEADERS TrialPascal Vranckx, Marco Valgimigli, Ayodele Odutayo, et al.
Pageof 97

Showing results (551-560 of 962) with videos related to

Sort By:
Pageof 97
Journal of the American College of Cardiology|March 23, 2019
Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-ITDeepak L Bhatt, Ph Gabriel Steg, Michael Miller, et al.
Critical Pathways in Cardiology|August 31, 2010
Prior cardiovascular interventions are not associated with worsened clinical outcomes in patients with symptomatic atherothrombosisWilliam E Boden, Gregory S Cherr, Kim A Eagle, et al.
Journal of the American College of Cardiology|January 14, 2017
Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary InterventionMuthiah Vaduganathan, Robert A Harrington, Gregg W Stone, et al.
Journal of the American College of Cardiology|October 2, 2012
Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgeryChristoph Varenhorst, Ulrica Alström, Benjamin M Scirica, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|October 9, 2017
Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trialsMuthiah Vaduganathan, Robert A Harrington, Gregg W Stone, et al.
Circulation. Cardiovascular Interventions|April 11, 2018
Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)Elliott M Groves, Deepak L Bhatt, Philippe Gabriel Steg, et al.
Heart (British Cardiac Society)|February 6, 2016
Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary interventionMatthijs A Velders, Jérémie Abtan, Dominick J Angiolillo, et al.
Journal of Thrombosis and Thrombolysis|June 14, 2017
Platelet-related biomarkers and their response to inhibition with aspirin and p2y<sub>12</sub>-receptor antagonists in patients with acute coronary syndromeAngela Lowenstern, Robert F Storey, Megan Neely, et al.
Clinical Chemistry|December 10, 2016
Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary SyndromeDaniel Lindholm, Stefan K James, Maria Bertilsson, et al.
Journal of the American Heart Association|September 17, 2021
Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre-Specified Analysis of the GLOBAL LEADERS TrialPascal Vranckx, Marco Valgimigli, Ayodele Odutayo, et al.
Pageof 97